The dose characteristics in the SIR-Spheres® Y-90 resin microspheres arm, were as follow:
|Average cumulative lung dose per patient (range), Gy||2.6 (1.2-4.8)|
|Average activity delivered per session (range), GBq||0.95 (0.63–1.22)|
|Average activity delivered per patient (range), GBq||1.39 (0.99–1.85)|
The activity was calculated using the modified Body-Surface Area (BSA) method.
71,7% of the treatments were lobar treatments and the majority (62,5%) were unilobar.
Patients with multiple sessions could have ipsi-lateral or contra-lateral treatment. 31.5% of the treatments were second-treatment and 6% were third-treatment, either ipsi- or contra-lateral.
In the sorafenib arm, the treatment characteristics were as follows:
|Dose intensity, median (IQR), mg||800 (585–800)|
|Cumulative time of intake, median (IQR), months||2.8 (1.0–5.8)|
|Sorafenib dose reduction||38%|
|Permanent discontinuation rate (PDR)||61%|
|Including PDR prior to tumour progression||37%|
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.